Neil Parikh, MD
Allergy & Immunology · Sacramento, CANPI 1952531030
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,480 of the $53,183 with a category attached, or 74.2%. AstraZeneca accounts for 70.0% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $22,601, 2.2 times the $10,166 reported in 2019. Among allergy & immunology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $264.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$37K
- Pharming Healthcare, Inc.$4K
- Sanofi$4K
- Optinose US, Inc.$4K
- Blueprint Medicines Corporation$2K
- CSL Behring$886
- plus $2K from 23 others
Across 15 payments — averaging $5538.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$43K
- Sanofi$28K
- Novartis$7K
- GSK$1K
- Shire North American Group Inc$1K
- Boehringer Ingelheim$1K
- plus $467 from 1 others
What the payments were for
- Consulting fees$4,7189%
- Speaking & faculty fees$39,48074%
- Travel & lodging$2,9356%
- Food & beverage$6,05011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $37,232 |
| Pharming Healthcare, Inc. | 5 | $3,938 |
| Sanofi | 17 | $3,742 |
| Optinose US, Inc. | 13 | $3,565 |
| Blueprint Medicines Corporation | 1 | $1,530 |
| CSL Behring | 10 | $886 |
| Regeneron Healthcare Solutions, Inc. | 10 | $437 |
| Alk-abello, Inc | 10 | $409 |
| GSK | 14 | $325 |
| Shire North American Group Inc | 8 | $164 |
| Octapharma USA, Inc. | 4 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $126 |
| Teva Pharmaceuticals USA, Inc. | 6 | $123 |
| Grifols USA, LLC | 5 | $112 |
| Covis Pharma GmbH | 4 | $78 |
| Philips North America LLC | 2 | $45 |
| Kaleo, Inc. | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 3 | $36 |
| Nestle Healthcare Nutrition Inc. | 1 | $35 |
| Biocryst Pharmaceuticals, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $26 |
| Genentech USA, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Hospira, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Novartis | 1 | $20 |
| Circassia Inc. | 1 | $13 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,183 in reported general payments places this provider in the 90th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 29 | $131,779 |
| Dupixent PenDupilumab | 23 | $85,492 |
| TezspireTezepelumab-Ekko | 12 | $50,576 |
| Dupixent SyringeDupilumab | 14 | $46,688 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $30,641 |
| Spiriva RespimatTiotropium Bromide | 35 | $20,561 |
| XhanceFluticasone Propionate | 12 | $17,732 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $14,038 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,206 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,831 |
| DuleraMometasone/Formoterol | 13 | $5,117 |
| Azelastine Hcl | 160 | $3,791 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,747 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $2,666 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $2,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort | $37,232 | $64,61463 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $325 | $49,42587 claims |
| Boehringer IngelheimSpiriva Respimat | $26 | $20,56135 claims |
| Optinose US, Inc.Xhance | $3,565 | $17,73212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Sacramento
- Raffi TachdjianSanta Monica$3.7M
- Bob GengSan Diego$3.3M
- Vinay MehtaLaguna Niguel$1.3M
- Andrew WhiteSan Diego$752K
- Marc RiedlSan Diego$725K
- Katharine WoessnerSan Diego$581K
- Brian Modenala Jolla$453K
- Heena Shah PatelUpland$428K
- Jacob OffenbergerGranada Hills$419K
- Myron LiebhaberSanta Barbara$354K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.